The Opportunity
The 2020 ASHP/IDSA guidelines mandate AUC-based vancomycin monitoring, yet most U.S. hospitals still use trough-only monitoring or expensive black-box tools. We built a transparent alternative.
$0M+
Global pharmacokinetic software market (StatsNData, 2025)
0
U.S. hospitals (AHA Fast Facts, 2026)
0%
Have NOT implemented AUC dosing (Brixner et al., 2022)
Our Solution: Vancomyzer™
The first AUC-guided vancomycin dosing platform that shows pharmacists every calculation. Built on the peer-reviewed Colin 2019 two-compartment population PK model, with an FFM-based obesity model (BMI ≥ 40) derived from Smit 2020 and Zhang 2024.
Transparent — every equation shown, every reference linked
Designed for community hospital budgets and individual clinicians
Guideline-compliant — 2020 ASHP/IDSA/PIDS
Traction
Pre-revenue, but not pre-product.
Full-stack web application built and functional
Colin 2019 PK model verified against published reference values
Legal & regulatory framework complete (21st Century Cures Act, Section 3060)
Mobile app (iOS & Android) targeted for Q3 2026
Business Model
SaaS tiers with a freemium funnel. Pricing positioned for community hospital budgets and individual clinicians who are priced out of enterprise platforms.
Free
$0
Students & individual clinicians
Individual Pro
$9.99–$19.99/mo
Pharmacists, physicians, NPs, PAs
Department / Hospital
Custom
Hospital pharmacy departments + health systems with EMR integration
Go-to-Market Strategy
Four customer-acquisition motions, each grounded in verifiable partnerships and assets we've already built — not speculative projections.
Hospital Pilot Program
Free 90-day pilots with community hospitals and HCA-affiliated facilities in South Texas. Converts pilot users to the Department / Hospital plan.
Direct Clinician Acquisition
Free tier draws individual pharmacists, physicians, NPs, and PAs. Pro tier conversion via clinical note export and unlimited calculations.
Academic & Research Partnerships
PharmD students from UT Austin’s regional internship program in South Texas and Texas A&M Rangel rotations. Joint case-study and validation publications with UTRGV School of Medicine residencies.
Content & SEO Engine
Authoritative clinical content (DOI-cited, guideline-aligned) drives organic acquisition of pharmacy directors evaluating AUC dosing tools.
Detailed financial modeling, customer pipeline, and unit economics are shared with qualified investors under NDA.
Capital Deployment
Where your investment goes. Round size, valuation, and terms are discussed directly with qualified investors.
Interested in investing in Dosys Health LLC? Reach out using the form below for a detailed conversation about round structure, terms, and milestones.
Team
Mario Cardenas
PharmD, MBA — Founder & CEO
Clinical pharmacist with expertise in vancomycin TDM and population PK. Designed the clinical logic, safety features, regulatory strategy, and product roadmap.
Key Hires Planned
- Lead Mobile Engineer (iOS/Android)
- Sales Lead — Hospital Pharmacy
- Clinical Advisory Board (3–5 members)
Interested in Dōsys?
Let's talk. We respond within 24 hours.